0001661059 false 0001661059 2022-06-23 2022-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 23, 2022


NextCure, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-38905   47-5231247

(State or other jurisdiction of


(Commission File Number)


(IRS Employer Identification No.)


9000 Virginia Manor Road, Suite 200

Beltsville, Maryland

(Address of principal
executive offices)
  (Zip Code)


Registrant’s telephone number, including area code: (240) 399-4900


(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading
Name of each exchange on which
Common Stock, $0.001 par value per share NXTC Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07.Submission of Matters to a Vote of Security Holders.


On June 23, 2022, NextCure, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters voted upon at the Annual Meeting and the final voting results for each matter as certified by the inspector of election.


Proposal No. 1: Election of Class III Directors


The Company’s stockholders elected David Kabakoff, Ph.D, Michael Richman and Stephen W. Webster as Class III members of the Company’s Board of Directors (the “Board”), each to serve for a three-year term expiring at the Company’s 2025 Annual Meeting of Stockholders, or until such director’s earlier death, resignation, or removal from the Board. The results of the votes were as follows:


Nominee  For   Against   Abstain   Broker Non-Votes 
David Kabakoff, Ph. D   11,548,824    1,187,004    245,392    4,783,701 
Michael Richman   11,609,302    1,124,238    247,680    4,783,701 
Stephen W. Webster   11,530,304    1,202,184    248,732    4,783,701 


Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm


The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the vote were as follows:


For   Against   Abstain   Broker Non-Votes 
 17,631,748    53,399    79,774    - 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: June 23, 2022


  By:      /s/ Steven P. Cobourn
  Name: Steven P. Cobourn
  Title: Chief Financial Officer